FluMist & Acambis pass advisory committee
Executive Summary
Both MedImmune's influenza virus vaccine FluMist and Acambis' live vaccinia virus smallpox vaccine ACAM2000 received positive recommendations from FDA's Vaccines and Related Biological Products Advisory Committee on May 16-17. The committee voted 9-6 that benefits of FluMist exceed risk in MedImmune's proposed population of children aged 12-59 months without a history of wheeze. ACAM2000 received unanimous approval for both safety and efficacy from the committee...
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.